Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Naloxone Model OTC Label Expected From US FDA As Part Of Opioids Strategy

Oct 23 2018

• By Eileen Francis

Related Content

FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap

May 16 2017

Opioid Blister-Pack Mandate Tops Gottlieb's Agenda With New Authority

Oct 22 2018

Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

Sep 06 2018

Related Companies

Kaléo Pharmaceutical Inc.

Adapt Pharma Limited

Purdue Pharma L.P.

Additional Topics

United States Prescription To OTC Switch Advisory Committees Drug Safety OTC Drugs Consumer Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window